Pulvinar Neuro awarded $3 million nih grant for transcranial stimulation research
Pulvinar Neuro is both honored and thrilled to share that we have been awarded a three-year, $3.06 million Phase II SBIR Grant from the NIH's National Institute of Mental Health (NIMH).
For more information, please click here.
Pulvinar Neuro, in partnership with Electromedical Products International, Inc. (EPI), is excited to announce that Dr. Leah Townsend, President of Pulvinar Neuro and Chief Science Officer of EPI, will be attending the 5th International Brain Stimulation Conference in Lisbon, Portugal (Saturday, February 18, 2023 - Wednesday, February 22, 2023). Dr. Townsend will have Pulvinar's next-generation research device, XCSITE-RD at Booth #29.
Stop by if you're attending to meet Dr. Townsend and discuss the future of non-invasive brain stimulation in psychiatry!
Flavio Frohlich, PhD, associate professor, UNC Neuroscience Center, and Founder of Pulvinar Neuro, and Leah Townsend, PhD, CEO of Pulvinar Neuro
We are excited to announce a strategic partnership with Electromedical Products International, Inc. (EPI), a leading medical device company using non-invasive brain stimulation to treat psychiatric disorders. This partnership will allow us to accelerate our non-invasive brain stimulation and product development, including transcranial alternating current stimulation (tACS), individualized feedback stimulation, and cloud-enabled therapeutics for the treatment of psychiatric and neurological illnesses.
I am looking forward to working with EPI to bring the next generation of personalized non-invasive brain stimulation to market, complementary with EPI's suites of devices, which we are confident will benefit millions of patients who are looking for effective and safe treatment options.
EPI is the market leader in low-current, non-invasive brain stimulation and has a long-standing track record of marketing its patented, FDA-cleared Alpha-Stim technology for the treatment of anxiety, insomnia, depression, and pain.
Closed-loop low-intensity transcranial stimulation for the treatment of CNS disorder has a very bright future ahead.
We are pleased to announce that Dr. Leah Townsend, PhD has joined us as Chief Executive Officer of Pulvinar Neuro. She previously served as a business consultant for Pulvinar Neuro and was instrumental in winning our Phase I NIMH grant (R43MH119872) to develop closed-loop tACS.
Dr. Townsend holds a PhD in Neurobiology from the University of North Carolina at Chapel Hill (UNC-CH) as well as both a BS in Psychology (summa cum laude) and BA in Philosophy (cum laude), also from UNC- CH.